Objectives: The UK & Ireland Implanters' registry is a multicenter registry which reports on realworld experience with novel transcatheter heart valves.
| INTRODUCTION
Transcatheter aortic valve replacement (TAVR) with a self-expanding prosthesis is a well-established therapy for the treatment of patients with severe aortic stenosis who are at extreme, high and intermediate-risk for surgery. [1] [2] [3] Until recently, patients with an aortic annulus diameter greater than 29 mm were not treatable with a selfexpanding prosthesis, and further, patients with an aortic annulus diameter greater than 29.5 mm were not treatable with any commercially available transcatheter aortic valve. 4 The 34 mm Evolut R transcatheter aortic valve (Medtronic, Minneapolis, Minnesota) is a second-generation transcatheter aortic valve which is designed to treat patients with an aortic annulus diameter between 26 and 30 mm. The key design changes from the firstgeneration CoreValve have been described previously. 5 In brief, the nitinol frame has been modified so that the inflow portion is wider and more cylindrical, providing more consistent radial force. The outflow portion is shorter and narrower, improving anatomical fit in highly angulated aortas. The porcine pericardial inflow skirt has been extended, with the aim of reducing paravalvular regurgitation. The valve is delivered using the 16-F equivalent EnVeo R delivery catheter system, which reduces the minimum transarterial access vessel diameter to 5.5 mm. The system may also be delivered through a 20-F introducer sheath. The nitinol delivery catheter capsule allows for resheathing and full recapture during deployment.
The UK & Ireland Implanters' registry is a multicenter registry which reports on real-world experience with novel transcatheter heart valves. Our group has previously reported on the procedural, clinical and 30-day outcome data of the 23, 26, and 29 mm Evolut R transcatheter aortic valves, which reflected our early experience with the Evolut R system between December 2013 and May 2016. 6 Here we describe our initial experience with the 34 mm Evolut R valve. 
| MATERIALS AND METHODS

| Procedural characteristics
Procedural characteristics are listed in Median length of stay post-procedure was 3 days (interquartile range 2-5 days).
| Device success
Overall device success was 79.7% (Table 3 ). There were two cases where a transcatheter aortic valve could not be deployed. One iliofemoral case had to be terminated due to an inability to advance the delivery catheter through the iliac vessels. One valve could not be deployed in a stable position in an aortic root homograft and was fully recaptured.
There were four cases which required a second prosthesis. In the first case the valve become invaginated after resheathing and would not re-expand. It was fully recaptured and a second 34 mm Evolut R prosthesis was placed without sequelae. In the second case (aortic annulus diameter 30.6 mm) the valve migrated on release to a depth of 15 mm and there was severe paravalvular regurgitation. While attempting to snare the prosthesis back into the aortic annulus, the valve embolized into the ascending aorta and a second 34 mm Evolut R valve was then deployed without sequelae. In the third case (aortic annulus diameter 25.1 mm), the valve embolized into the ascending aorta upon device release and a second 34 mm Evolut R valve was deployed without complication. In the fourth case (aortic annulus diameter 28.5 mm) the valve migrated on release to a depth of 20 mm, which was associated with severe paravalvular regurgitation.
Two additional 34 mm Evolut R prostheses were deployed, reducing paravalvular regurgitation to moderate.
There were an additional three cases of valve migration, all of which occurred immediately after final release (Table 4 ). There were no cases of coronary occlusion, annular rupture, ventricular perforation, or need for sternotomy.
| Early safety
Early safety was demonstrated in 91.2%. (Table 3 ). There were no immediate procedural mortalities, but seven patients ( 
| Secondary outcomes
| Outcomes in bicuspid patients
Twelve patients were treated for bicuspid aortic stenosis. One patient development moderate paravalvular regurgitation (8.3%) and two patients required permanent pacemaker implanation (22.9% of patients without a pacemaker at baseline). Early safety was demonstrated in all patients.
| Outcomes in pure aortic regurgitation
Four inoperable patients were treated for pure aortic regurgitation.
Device annular sizing ratio was 28.3% AE 2.6%. There were no cases of moderate paravalvular regurgitation and two patients (50.0%) required permanent pacemaker implantation. There was one case of valve migration as has previously been discussed. Early safety was demonstrated in all patients. 
| Risk factors for complications
| Comparison to the 23, 26, and 29 mm valve sizes
When compared with our previous experience of the smaller valve sizes, patients in the 34 mm registry had broadly similar baseline characteristics, but with some important differences (Supporting Information Table S1 ). The 34 mm group had a higher proportion of men and a higher prevalence of pre-existing permanent pacemaker or defibrillator. Fewer valve-in-valve procedures were undertaken with the 34 mm valve size.
Procedural differences were noted between the two cohorts (Supporting Information Table S2 ). The 34 mm valve procedures, which were undertaken in a more contemporary time period, were more frequently performed under local anesthesia or conscious sedation. The larger valve size saw more frequent usage of the EnVeo R delivery catheter without an introducer sheath. Both pre-implant balloon valvuloplasty and use of the EnVeo R delivery system's resheathing and recapture function were more common with the 34 mm valve size.
Device success, early safety, more than mild paravalvular regurgitation and new permanent pacemaker implantation were all similar between the two cohorts (Supporting Information Table S3 ). Mean aortic valve gradient was lower (7.0 AE 4.6 vs. 8.3 AE 6.0 mmHg, P = .02) and effective orifice area was larger (2.0 AE 0.6 vs. 1.7 AE 0.5 cm 2 , P < .001) with the 34 mm valve size.
| DISCUSSION
We describe here the clinical, procedural and 30-day outcome data of a large cohort of consecutive, real-world patients treated with the 34 mm Evolut R transcatheter aortic valve. Procedural indications
were broad, and we demonstrated successful implantations in bioprosthetic surgical valves, aortic root homografts, pure native aortic regurgitation and bicuspid aortic valve morphology.
Valve implantation demonstrated a favorable safety profile (allcause mortality 3.2%, stroke 3.7%, life-threatening bleeding 0.9%, and major vascular complication 2.3%).
Device success (79.7%) was similar to our experience with the smaller valve sizes (72.3%) and outcomes reported in the Evolut R CE Mark clinical trial (78.6%). 8 Patient-prosthesis mismatch (7.8%) was the largest driver for an unsuccessful procedure, the incidence of which was lower than our experience with the smaller valve sizes Valve hemodynamics were excellent with a low mean aortic valve gradient (7.0 AE 4.6 mmHg) and large effective orifice area (2.0 AE 0.6 cm 2 ). Only three patients had a mean aortic valve gradient ≥20 mmHg or peak velocity ≥3 m/sec.
Incidence of more than mild paravalvular regurgitation at 30-days (7.2%) was similar to our experience with the smaller valve sizes (7.8%) and outcomes reported in both the Evolut R CE Mark (6.7%)
and Evolut R U.S. (5.3%) clinical studies. 8, 9 These findings represent a definite improvement on the outcomes seen with the first-generation
CoreValve in the ADVANCE clinical study (15.0%). 10 However, incidence of more than mild paravalvular regurgitation was not as low as has been recently reported in the Evolut R FORWARD clinical study (1.9%), Evolut R 34 mm U.S. clinical study (1.7%), Evolut PRO U.S. clinical study (0.0%) and other 34 mm Evolut R registry data (0.0%-5.0%).
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The average implant depth in our study (5.6 AE 3.1 mm) was outside the manufacturer recommendations (3-5 mm), which may explain the higher incidence of more than mild paravalvular regurgitation that we have reported. A 34 mm Evolut PRO valve is currently in development, which should reduce this complication.
Incidence of new permanent pacemaker insertion (15.7%) was similar to our experience of the smaller Evolut R prosthesis sizes.
However, pre-existing permanent pacemaker was more common in patients treated with the 34 mm prosthesis, perhaps reflective of an increased tendency for operators to implant prophylactic pacemakers.
The resheating and recapture ability was frequently used to optimize positioning (27.2%) and in two cases was employed to completely remove the transcatheter aortic valve from the patient.
Usage of these features was more common than with our previous experience of the smaller valve sizes, which probably reflects greater operator experience using this technology, but may also be indicative of the difficulties in placing transcatheter aortic valves in large anatomy, due to an increased prevalence of excessive aortic root angulation.
The 16-F equivalent EnVeo R delivery catheter system is larger than the 14-F equivalent system used for the 23 to 29 mm Evolut R valves. However, as iliofemoral vessels were larger in this cohort, iliofemoral access rates were similar and major vascular complications remained low (2.3%). More 34 mm procedures were performed without an introducer sheath, likely reflecting greater operator familiarity using the in-line sheath feature of the EnVeo R delivery system.
Valve embolization occurred in two patients, both whom had aortic annulus dimensions outside the manufacturer recommended sizing algorithm. A second 34 mm Evolut R prosthesis was successfully implanted in both cases.
Pre-existing right bundle branch block and a low implant depth are both well-established risk factor for new permanent pacemaker implantation after TAVR. 17 We confirmed that these clinical and procedural characteristics were both associated with new permanent pacemaker implantation after TAVR with the 34 mm Evolut R valve.
Device annular sizing ratio was associated with the development of more than mild paravalvular regurgitation, as has previously been described. 9 The incidence of moderate paravalvular regurgitation reported in this study (7.2%) was similar to a recent series of large annuli patients treated with the SAPIEN 3 valve (6.9%) (Edwards Lifesciences, Irvine, California), but incidence of permanent pacemaker was higher with the self-expanding prosthesis (15.7% vs. 6.3%). 18 
| Limitations
This study should be interpreted within the inherent constraints of a registry. All clinical outcomes were site reported. There was no usage of a core laboratory for assessing echocardiographic outcomes. Echocardiographic and clinical follow-up information was not available for all patients. Further work is needed to establish long-term prosthesis durability.
However, this study has considerable strengths, specifically the prospective, consecutive data collection on real-world, unselected patients, that reflect day-to-day clinical practice.
| CONCLUSION
In this study we have described our initial experience of a large, selfexpanding, and fully recapturable transcatheter aortic valve. Procedural success, safety, valve function, and incidence of new permanent pacemaker implantation were all acceptable and similar to previous studies of the Evolut R prosthesis.
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